03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Increlex : | |
Type | TAU |
Originator | B |
Agent | Droguerie de l'Union |
Distributor | Droguerie de l'Union |
Laboratory | Ipsen Pharma |
Manufacturer | Ipsen Pharma Biotech |
Origin | France |
ATC | H01AC03 |
Increlex :
Increlex :
Increlex :
Increlex :
Increlex :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Increlex :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal pain | Common |
Abdominal pain upper | Very Common |
Adenoidal hypertrophy | Common |
Alopecia | Not known |
Anaphylaxis | Not known |
Angioedema (Angioneurotic oedema) (Quincke oedema) | Not known |
Arthralgia (Pain joint) (Joint ache) | Very Common |
Benign intracranial hypertension | Uncommon |
Cardiac murmur | Common |
Cardiomegaly | Uncommon |
Convulsion | Common |
Depression | Uncommon |
Dizziness | Common |
Drug specific antibody present | Not known |
Dyspnoea (dyspnea) | Common |
Ear tube insertion | Common |
Gynecomastia (Gynaecomastia) | Common |
Hair texture abnormal | Common |
Headache | Very Common |
Hyperglycaemia | Common |
Hypersensitivity | Not known |
Hypoacusis | Common |
Hypoglycaemia | Very Common |
Hypoglycaemic seizure | Common |
Injection site bruising | Very Common |
Injection site erythema | Common |
Injection site haematoma | Common |
Injection site haemorrhage | Common |
Injection site hypertrophy | Very Common |
Injection site induration | Common |
Injection site irritation | Common |
Injection site pain | Common |
Injection site pruritus | Not known |
Injection site rash | Uncommon |
Injection site reaction | Common |
Injection site swelling | Common |
Injection site urticaria | Not known |
Lipohypertrophy | Uncommon |
Melanocytic naevus | Common |
Middle ear effusion | Common |
Mitral valve incompetence | Uncommon |
Myalgia | Common |
Nervousness | Uncommon |
Otalgia (Earache) (Ear pain) | Common |
Otitis media | Very Common |
Pain in extremity (Pain in limb) | Very Common |
Papilloedema | Common |
Scoliosis | Common |
Skin hypertrophy | Common |
Sleep apnoea syndrome | Common |
Snoring | Common |
Tachycardia | Common |
Thymus enlargement | Common |
Tonsillar hypertrophy | Common |
Tremor | Common |
Tricuspid valve incompetence | Uncommon |
Urticaria generalised | Not known |
Ventricular hypertrophy | Uncommon |
Vomiting | Very Common |
Weight increased (weight gain) | Uncommon |
Increlex :
Different Units By MoH Code
Increlex MoH 2060018 :
Form | Powder for solution for injection |
Packaging | Bottle |
Package Size | 1x4ml |
Strength | 40mg |
Stratum | N/A |
NSSF | ✘ |
Quarantine | ✘ |
Price Comparison
You have to register to view this info
You have to register to view this info
You have to register to view this info
You have to register to view this info
You have to register to view this info
You have to register to view this info
You have to register to view this info
You have to register to view this info
Note
You have to register to view this info
Drop File